Idilman R, et al. - Ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin was investigated regarding its efficacy and tolerability in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease. In addition, researchers examined the association of the use of LDV/SOF treatment with a new occurrence of hepatocellular carcinoma (HCC). During the Turkish Early Access Program, a total of 200 eligible CHC patients with the advanced liver disease received LDV/SOF treatment. The sustained virological response of 86.0% was noted in ITT analysis. Findings support the efficacy of and tolerability to LDV/SOF with or without ribavirin treatment in these patients. Improvements in liver function and a reduced risk of developing a new occurrence of HCC were noted in correlation to eradication.